THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurooncol Adv
Autori principali: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Pennell, Nathan, Stevens, Glen, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213262/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz014.052
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi